【摘要】：背景病毒性心肌炎(viral myocarditis,VMC)是最為常見的心肌炎類型,主要是由柯薩奇病毒B(Coxsackievirus B,CVB)所引發(fā)。相關(guān)統(tǒng)計(jì)資料表明,造成嬰兒猝死的疾病中大約有20%是由病毒性心肌炎或者由其引發(fā)的致死性室性心律失常所引起,且持續(xù)活動(dòng)的病毒性心肌炎患者的預(yù)后情況通常較不理想,嚴(yán)重威脅兒童生命健康。當(dāng)機(jī)體發(fā)生持續(xù)性慢性炎癥時(shí),往往能夠造成心肌細(xì)胞生長(zhǎng)抑制、肥大、凋亡率增高,此外還會(huì)進(jìn)一步引發(fā)心肌纖維化、擴(kuò)張型心肌病以及心力衰竭等。迄今為止,國(guó)內(nèi)外依然缺乏治療病毒性心肌炎的有效手段,因此,尋找診斷病毒性心肌炎的分子標(biāo)志物有助于提前采取有效措施減緩或抑制該病的進(jìn)展,同時(shí)還能以此作為分子靶標(biāo)達(dá)到治療的目的。mi R-19b屬于mi RNA家族成員,在進(jìn)化上高度保守,在多種生物的胚胎心臟中均有表達(dá)。以往研究表明mi R-19b的表達(dá)缺失時(shí),能夠?qū)е滦律∈笫议g隔缺損,提示mi R-19b可能參與了早期心臟發(fā)育過(guò)程。提示mi R-19b可能在早期即參與了心臟發(fā)育過(guò)程。也有研究表明,mi R-19b的表達(dá)水平在擴(kuò)張型心肌病患者心肌重構(gòu)的心肌組織中發(fā)生顯著上調(diào)。盡管mi R-19b在心臟發(fā)育過(guò)程中發(fā)揮著重要作用,但目前有關(guān)mi R-19b與病毒性心肌炎發(fā)生和發(fā)展相關(guān)性的研究依然相對(duì)較少。目的本研究探討病毒性心肌炎患兒循環(huán)血中mi R-19b的表達(dá)變化及其與心肌病變嚴(yán)重程度的相關(guān)性,同時(shí)分析其表達(dá)對(duì)心肌細(xì)胞增殖和凋亡的影響,并對(duì)其中的相關(guān)機(jī)制進(jìn)行研究,旨在為病毒性心肌炎的臨床診斷及開發(fā)新的靶向治療藥物奠定基礎(chǔ)。方法(1)本研究采集來(lái)自于2014年6月~2015年6月在吉林大學(xué)第一醫(yī)院住院收治的病毒性心肌炎患兒外周血,共50例。熒光定量PCR檢測(cè)外周血樣本中mi R-19b表達(dá);檢測(cè)血清中c Tn I和CK-MB的表達(dá);測(cè)定患兒左心室射血分?jǐn)?shù)(EF)和短軸縮短率(FS);分析mi R-19b表達(dá)與上述檢測(cè)指標(biāo)的相關(guān)性。(2)采用酶兩步消化法分離培養(yǎng)原代SD大鼠乳鼠心肌細(xì)胞。將mi R-19b mimic和mi R-19b inhibitor轉(zhuǎn)染上述細(xì)胞,熒光定量PCR檢測(cè)轉(zhuǎn)染后細(xì)胞中mi R-19b的表達(dá)。將CVB3感染上述細(xì)胞,CCK-8實(shí)驗(yàn)檢測(cè)細(xì)胞增殖活性,流式細(xì)胞術(shù)檢測(cè)細(xì)胞凋亡率。運(yùn)用生物信息學(xué)軟件預(yù)測(cè)mi R-19b的靶基因,構(gòu)建含有熒光素酶報(bào)告基因的TLR23’UTR(野生型)和TLR2 3’UTR-mut(突變型)質(zhì)粒,并將之分別與mi R-19b mimic共轉(zhuǎn)染乳鼠心肌細(xì)胞,檢測(cè)上述細(xì)胞中熒光素酶的表達(dá)。分別將mi R-19b mimic和mi R-19b inhibitor共轉(zhuǎn)染乳鼠細(xì)胞,隨后用CVB3感染上述細(xì)胞,檢測(cè)細(xì)胞中TLR2m RNA和蛋白的表達(dá)。(3)構(gòu)建mi R-19b過(guò)表達(dá)病毒性心肌炎大鼠模型,檢測(cè)上述模型大鼠心肌組織中mi R-19b的表達(dá)。將CVB3分別感染上述大鼠模型以及正常SD大鼠,HE染色法觀察心肌組織病理學(xué)變化,TUNEL染色法檢測(cè)心肌細(xì)胞凋亡,western blot法檢測(cè)TLR2蛋白的表達(dá)。結(jié)果(1)在重癥VMC組中,恢復(fù)期時(shí)血漿mi R-19b的表達(dá)量明顯高于急性期;在輕癥VMC組中,恢復(fù)期時(shí)血漿mi R-19b的表達(dá)量明顯高于急性期。病毒性心肌炎患兒血清中c Tn I水平明顯高于對(duì)照組患兒。在重癥VMC組中,恢復(fù)期時(shí)血清c Tn I水平明顯低于急性期;在重癥VMC組中,恢復(fù)期時(shí)血清c Tn I水平明顯低于急性期。病毒性心肌炎患兒血清中CK-MB水平明顯高于對(duì)照組患兒。在重癥VMC組中,恢復(fù)期時(shí)血清CK-MB水平明顯低于急性期;在輕癥VMC組中,恢復(fù)期時(shí)血清CK-MB水平明顯低于急性期。EF檢測(cè)結(jié)果表明,重癥期患兒EF明顯低于對(duì)照組;重癥VMC組恢復(fù)期患兒EF與對(duì)照組相比無(wú)顯著差異;輕癥VMC組急性期患兒EF與對(duì)照組相比無(wú)明顯差異;輕癥VMC組恢復(fù)期患兒與對(duì)照組相比無(wú)顯著差異。重癥VMC患兒急性期血漿mi R-19b表達(dá)水平與血清c Tn I含量呈負(fù)相關(guān),重癥VMC患兒恢復(fù)期血漿mi R-19b表達(dá)水平與血清c Tn I含量無(wú)明顯相關(guān)性;輕癥VMC患兒急性期血漿mi R-19b表達(dá)水平與血清c Tn I含量呈負(fù)相關(guān),輕癥VMC患兒恢復(fù)期血漿mi R-19b表達(dá)水平與血清c Tn I含量無(wú)明顯相關(guān)性。而對(duì)照組患兒血漿mi R-19b表達(dá)水平與血清c Tn I含量無(wú)顯著相關(guān)性。重癥VMC患兒急性期血漿mi R-19b表達(dá)水平與血清CK-MB含量呈負(fù)相關(guān),重癥VMC患兒恢復(fù)期血漿mi R-19b表達(dá)水平與血清CK-MB含量無(wú)明顯相關(guān)性;輕癥VMC患兒急性期血漿mi R-19b表達(dá)水平與血清CK-MB含量呈負(fù)相關(guān),輕癥VMC患兒恢復(fù)期血漿mi R-19b表達(dá)水平與血清CK-MB含量無(wú)明顯相關(guān)性。對(duì)照組患兒血漿mi R-19b表達(dá)水平與血清CK-MB含量無(wú)顯著相關(guān)性。重癥VMC患兒急性期血漿mi R-19b含量與EF之間存在明顯正相關(guān),重癥VMC患兒恢復(fù)期血漿mi R-19b表達(dá)水平與EF之間無(wú)顯著相關(guān)性;輕癥VMC患兒急性期血漿mi R-19b含量與EF之間無(wú)明顯相關(guān)性,輕癥VMC患兒恢復(fù)期血漿mi R-19b表達(dá)水平與EF之間無(wú)顯著相關(guān)性。對(duì)照組患兒血漿mi R-19b表達(dá)水平與血清EF含量無(wú)顯著相關(guān)性。重癥VMC患兒急性期血漿mi R-19b含量與FS之間存在明顯正相關(guān),重癥VMC患兒恢復(fù)期血漿mi R-19b表達(dá)水平與FS之間無(wú)顯著相關(guān)性;輕癥VMC患兒急性期血漿mi R-19b含量與FS之間無(wú)明顯相關(guān)性,輕癥VMC患兒恢復(fù)期血漿mi R-19b表達(dá)水平與FS之間無(wú)顯著相關(guān)性。對(duì)照組患兒血漿mi R-19b表達(dá)水平與血清FS含量無(wú)顯著相關(guān)性。(2)轉(zhuǎn)染mi R-19b mimic后乳鼠心肌細(xì)胞中mi R-19b的表達(dá)明顯高于對(duì)照組;轉(zhuǎn)染mi R-19b inhibitor后乳鼠心肌細(xì)胞中mi R-19b的表達(dá)明顯低于對(duì)照組。與對(duì)照組相比,mi R-19b mimic組在48 h、72 h、96 h時(shí)的存活率均明顯增高,而mi R-19b inhibitor組相應(yīng)時(shí)間點(diǎn)時(shí)的存活率均明顯降低。與對(duì)照組相比,mi R-19b mimic組細(xì)胞的凋亡率明顯降低,mi R-19b inhibitor組細(xì)胞的凋亡率明顯增高。TLR2為mi R-19b的靶基因。構(gòu)建的攜帶有熒光素酶報(bào)告基因的野生型TLR2 3’UTR載體與mi R-19b mimic共轉(zhuǎn)染乳鼠心肌細(xì)胞后細(xì)胞中熒光素酶表達(dá)水平明顯降低,而突變型TLR2 3’UTR載體與mi R-19b mimic共轉(zhuǎn)染后細(xì)胞中熒光素酶的表達(dá)量則無(wú)明顯變化。TLR m RNA檢測(cè)結(jié)果表明,與對(duì)照組相比,mi R-19b mimic組細(xì)胞中TLR m RNA的表達(dá)水平明顯降低,而mi R-19b inhibitor組細(xì)胞中TLR m RNA的表達(dá)水平明顯增高。TLR2蛋白檢測(cè)結(jié)果表明,與對(duì)照組相比,mi R-19b mimic組細(xì)胞中TLR蛋白的表達(dá)水平明顯降低,而mi R-19b inhibitor組細(xì)胞中TLR蛋白的表達(dá)水平明顯升高。(3)轉(zhuǎn)基因大鼠模型心肌組織中mi R-19b的表達(dá)水平明顯高于對(duì)照組。正常SD大鼠在感染CVB3后大量心肌細(xì)胞發(fā)生壞死崩解,細(xì)胞核以及細(xì)胞輪廓消失,在心肌細(xì)胞間隙內(nèi)可觀察到大量炎癥細(xì)胞浸潤(rùn),且浸潤(rùn)部位心肌纖維排列紊亂,心肌組織被破壞。心肌炎轉(zhuǎn)基因大鼠感染CVB3后心肌細(xì)胞崩解數(shù)量顯著減少,細(xì)胞核和細(xì)胞輪廓較為清晰,心肌細(xì)胞間隙可見少量炎性細(xì)胞浸潤(rùn)。感染CVB3后心肌炎轉(zhuǎn)基因大鼠心肌細(xì)胞的凋亡率明顯低于正常SD大鼠。感染CVB3后心肌炎轉(zhuǎn)基因大鼠心肌組織中TLR2蛋白的表達(dá)明顯低于正常SD大鼠。結(jié)論(1)mi R-19b在病毒性心肌炎中表達(dá)降低;(2)mi R-19b與病毒性心肌炎疾病嚴(yán)重程度及病程相關(guān);(3)mi R-19b通過(guò)靶向抑制TLR2的表達(dá)促進(jìn)心肌細(xì)胞增殖,抑制其凋亡,從而抑制病毒性心肌炎的發(fā)展。(4)mi R-19b對(duì)由CVB3感染所引起的心肌細(xì)胞損傷具有保護(hù)作用,其機(jī)制與mi R-19b抑制TLR2蛋白的表達(dá),從而減輕心肌細(xì)胞炎癥反應(yīng),抑制心肌細(xì)胞凋亡有關(guān)。
[Abstract]:Background Viral myocarditis (VMC) is the most common type of myocarditis, mainly caused by Coxsackievirus B (CVB). Statistics show that about 20% of the sudden infant death is caused by viral myocarditis or lethal ventricular arrhythmias caused by viral myocarditis and persists. The prognosis of active viral myocarditis is usually unsatisfactory, which seriously threatens the life and health of children. When persistent chronic inflammation occurs, it often leads to myocardial cell growth inhibition, hypertrophy, increased apoptosis rate, and further leads to myocardial fibrosis, dilated cardiomyopathy and heart failure. However, there is still no effective method to treat viral myocarditis at home and abroad. Therefore, looking for molecular markers for diagnosis of viral myocarditis is helpful to take effective measures to slow down or inhibit the progress of the disease, and can also be used as a molecular target to achieve the purpose of treatment. Previous studies have shown that the absence of MIR-19b expression can lead to ventricular septal defect in neonatal mice, suggesting that MIR-19b may be involved in early cardiac development. Although mi R-19b plays an important role in cardiac development, there are few studies on the relationship between MI R-19b and the occurrence and development of viral myocarditis. Objective To investigate the expression of MI R-19b in circulating blood of children with viral myocarditis. The aim of this study is to lay a foundation for the clinical diagnosis of viral myocarditis and the development of new targeted therapies. Methods (1) This study was collected from June 2014 to June 2015. Fifty children with viral myocarditis were hospitalized in the First Hospital of Jilin University.The expression of MI R-19b in peripheral blood samples was detected by fluorescence quantitative PCR.The expressions of C Tn I and CK-MB in serum were detected.The left ventricular ejection fraction (EF) and short axis shortening rate (FS) were measured. MiR-19b mimic and MI R-19b inhibitor were transfected into these cells. The expression of MI R-19b in the transfected cells was detected by fluorescence quantitative PCR. CVB3 was infected with these cells. Cell proliferation activity was detected by CCK-8 assay and apoptosis rate was detected by flow cytometry. The target gene of MI R-19b was predicted by software. TLR23'UTR (wild type) and TLR23'UTR-mut (mutant type) plasmids containing luciferase reporter gene were constructed and co-transfected with MI R-19b mimic to detect the expression of luciferase in neonatal rat cardiomyocytes. Then the above cells were infected with CVB3 and the expression of TLR2m RNA and protein was detected. (3) A rat model of viral myocarditis with overexpression of MIR-19b was established to detect the expression of MIR-19b in the myocardium of the above-mentioned model rats. Results (1) In severe VMC group, the expression of plasma MIR-19b was significantly higher in convalescence than in acute phase; in mild VMC group, the expression of plasma MIR-19b was significantly higher in convalescence than in acute phase. In the severe VMC group, the serum levels of C Tn I in convalescent stage were significantly lower than those in acute stage; in the severe VMC group, the serum levels of C Tn I in convalescent stage were significantly lower than those in acute stage. In mild VMC group, the serum CK-MB level was significantly lower in convalescent stage than in acute stage. EF test results showed that EF in severe VMC group was significantly lower than that in control group; EF in convalescent stage in severe VMC group was not significantly different from that in control group; EF in mild VMC group was not significantly different from that in acute stage; EF in convalescent stage in mild VMC group was significantly lower than that in control group. There was no significant difference between the two groups. There was a negative correlation between the level of plasma MIR-19b and the level of serum C Tn I in the acute stage of severe VMC. There was no significant correlation between the level of plasma MIR-19b and the level of serum C Tn I in the convalescent stage of severe VMC. There was a negative correlation between the level of plasma MIR-19b and the level of serum C Tn I in the acute stage of mild VMC. There was no significant correlation between the levels of plasma M I R-19b and serum C Tn I in the acute phase of severe VMC, but no significant correlation between the levels of plasma M I R-19b and serum C Tn I in the control group. There was no significant correlation between the levels of serum CK-MB and the levels of plasma MIR-19b in mild VMC. There was no significant correlation between the levels of serum CK-MB and the levels of plasma MIR-19b in convalescent VMC. There was no significant correlation between the level of plasma MIR-19b and EF in the convalescent stage of severe VMC, but no significant correlation between the level of plasma MIR-19b and EF in the acute stage of mild VMC, and no significant correlation between the level of plasma MIR-19b and EF in the convalescent stage of mild VMC. There was no significant correlation between the levels of plasma MIR-19b and serum EF. There was a positive correlation between the levels of plasma MIR-19b and FS in the acute stage of severe VMC. There was no significant correlation between the levels of plasma MIR-19b and FS in the convalescent stage of severe VMC. There was no significant correlation between the expression of MIR-19b and FS in the convalescent stage of mild VMC. There was no significant correlation between the expression of MIR-19b and FS in the control group. Compared with the control group, the survival rate of MIR-19b mimic group was significantly higher at 48, 72 and 96 hours, while that of MIR-19b inhibitor group was significantly lower at corresponding time points. TLR2 was the target gene of MI R-19b. The expression level of luciferase in neonatal rat cardiomyocytes co-transfected with wild-type TLR2 3'UTR vector carrying luciferase reporter gene and MI R-19b mimic was significantly decreased, but the expression level of luciferase in neonatal rat cardiomyocytes co-transfected with mutant TLR2 3'UTR vector and mir-19b mic was not found. The results of TLR-m RNA detection showed that the expression of TLR-m RNA in the cells of MIR-19b mimic group was significantly lower than that of the control group, while the expression of TLR-m RNA in the cells of MIR-19b inhibitor group was significantly higher than that of the control group. (3) The expression of MIR-19b in the myocardium of transgenic rats was significantly higher than that of the control group. After infection with CVB3, a large number of myocardial cells in normal SD rats necrosis and disintegration, nucleus and cell contour disappeared, and the expression of TLR protein in the myocardial interspace was observed. A large number of inflammatory cells were infiltrated, and the myocardial fibers were arranged disorderly in the infiltration site, and the myocardial tissue was destroyed. The number of myocardial cells disintegrated significantly after the infection of CVB3 in transgenic myocarditis rats, the nucleus and cell contour were clearer, and a small amount of inflammatory cells infiltrated into the myocardial space. The expression of TLR2 protein in myocardium of transgenic rats infected with CVB3 was significantly lower than that of normal SD rats. Conclusion (1) The expression of MIR-19b was decreased in viral myocarditis; (2) MIR-19b was associated with the severity and course of viral myocarditis; (3) MIR-19b was promoted by targeting inhibition of TLR2 expression. (4) MIR-19b has protective effect on myocardial cell injury caused by CVB3 infection, and its mechanism is related to the inhibition of TLR2 protein expression by MIR-19b, which can alleviate myocardial inflammation and inhibit cardiomyocyte apoptosis.
【學(xué)位授予單位】：吉林大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2017
【分類號(hào)】：R542.21

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 莫祥蘭,劉時(shí)才;病毒性心肌炎(附一例報(bào)告)[J];廣西醫(yī)學(xué);2000年05期

2 馬正義,郭彩云;中西醫(yī)結(jié)合治療病毒性心肌炎36例[J];河北中醫(yī);2000年02期

3 韋洪林,線麗波,于景峰;中西醫(yī)結(jié)合治療病毒性心肌炎療效觀察[J];黑龍江醫(yī)學(xué);2000年03期

4 谷俊,韓冬;病毒性心肌炎合并Ⅱ°～Ⅲ°房室傳導(dǎo)阻滯15例臨床分析[J];錦州醫(yī)學(xué)院學(xué)報(bào);2000年03期

5 陳淑華,曹文君;中西醫(yī)結(jié)合治療病毒性心肌炎62例[J];黑龍江醫(yī)藥科學(xué);2000年02期

6 白秋彩,董良璞;病毒性心肌炎50例臨床分析[J];中原醫(yī)刊;2000年09期

7 ;警惕病毒性心肌炎[J];農(nóng)村實(shí)用技術(shù)與信息;2000年12期

8 吳貴秋,米麗娟,關(guān)東英;應(yīng)用果糖二磷酸鈉注射液治療病毒性心肌炎的效果觀察[J];齊齊哈爾醫(yī)學(xué)院學(xué)報(bào);2000年04期

9 ;病毒性心肌炎診斷有了客觀標(biāo)準(zhǔn)[J];山東中醫(yī)藥大學(xué)學(xué)報(bào);2000年04期

10 崔秋穎,畢風(fēng)麗;中西醫(yī)結(jié)合治療病毒性心肌炎48例[J];心血管康復(fù)醫(yī)學(xué)雜志;2000年01期

相關(guān)會(huì)議論文 前10條

1 關(guān)鍵;王國(guó)干;孫筱璐;;強(qiáng)的松對(duì)病毒性心肌炎的保護(hù)作用[A];第三屆重癥醫(yī)學(xué)大會(huì)論文匯編[C];2009年

2 陳其;張園海;仇慧仙;翁海美;夏天和;任躍;花旺;姜?jiǎng)Ρ?榮星;吳蓉洲;;胱硫醚-γ-裂解酶/硫化氫通路在小鼠病毒性心肌炎中的表達(dá)[A];中華醫(yī)學(xué)會(huì)第十五次全國(guó)兒科學(xué)術(shù)大會(huì)論文匯編（上冊(cè)）[C];2010年

3 王連偉;張勇剛;高立功;李海明;龔全友;;654-2在病毒性心肌炎Ⅲ°房室傳導(dǎo)阻滯中的應(yīng)用[A];中華醫(yī)學(xué)會(huì)急診醫(yī)學(xué)學(xué)會(huì)第六次全國(guó)急診醫(yī)學(xué)學(xué)術(shù)會(huì)議論文匯編[C];1996年

4 張廣文;白雪;楊思進(jìn);;中藥抗病毒性心肌炎的實(shí)驗(yàn)研究現(xiàn)狀[A];第九次全國(guó)中醫(yī)心病學(xué)術(shù)研討會(huì)論文精選[C];2007年

5 徐海鷹;凌峰;于忠;許軼洲;楊俊;;病毒性心肌炎患者細(xì)胞免疫功能檢測(cè)的臨床價(jià)值[A];2012年浙江省心電生理與起搏學(xué)術(shù)年會(huì)論文集[C];2012年

6 胡以明;;中西醫(yī)結(jié)合治療氣陰兩虛型病毒性心肌炎臨床體會(huì)[A];中國(guó)中醫(yī)藥學(xué)會(huì)內(nèi)科學(xué)會(huì)第三屆學(xué)術(shù)年會(huì)論文集[C];1997年

7 李宏圖;;1+X治療病毒性心肌炎的體會(huì)[A];中醫(yī)藥學(xué)術(shù)發(fā)展大會(huì)論文集[C];2005年

8 韓麗華;曾垂義;;144例病毒性心肌炎急性期病例分析[A];中華中醫(yī)藥學(xué)會(huì)內(nèi)科分會(huì)學(xué)術(shù)年會(huì)資料匯編[C];2007年

9 張軍平;周亞男;;成人病毒性心肌炎患者40例臨床觀察分析[A];中華中醫(yī)藥學(xué)會(huì)心病分會(huì)第十一屆學(xué)術(shù)年會(huì)論文精選[C];2009年

10 呂仕超;張軍平;;病毒性心肌炎診斷的困惑與對(duì)策[A];中華中醫(yī)藥學(xué)會(huì)心病分會(huì)全國(guó)第十二次學(xué)術(shù)年會(huì)暨中華中醫(yī)藥學(xué)會(huì)心病分會(huì)換屆選舉工作會(huì)議論文精選[C];2010年

相關(guān)重要報(bào)紙文章 前10條

1 李尤佳;病毒性心肌炎病后加強(qiáng)護(hù)理[N];健康時(shí)報(bào);2007年

2 王小衡;病毒性心肌炎好發(fā)青年女子[N];大眾衛(wèi)生報(bào);2007年

3 喬國(guó)維;病毒性心肌炎運(yùn)動(dòng)療[N];醫(yī)藥養(yǎng)生保健報(bào);2007年

4 ;患病毒性心肌炎宜多靜養(yǎng)[N];醫(yī)藥導(dǎo)報(bào);2008年

5 上海承志堂中醫(yī)館 朱邦賢 教授;“病毒性心肌炎”中醫(yī)可防可治[N];上海中醫(yī)藥報(bào);2009年

6 李尤佳;病毒性心肌炎不可小看[N];中國(guó)中醫(yī)藥報(bào);2004年

7 伍新華;大黃有望成為病毒性心肌炎克星[N];大眾衛(wèi)生報(bào);2005年

8 秦 秋;中醫(yī)藥治療病毒性心肌炎取得成果[N];中國(guó)中醫(yī)藥報(bào);2004年

9 何世楨;病毒性心肌炎患者宜靜養(yǎng)[N];中國(guó)中醫(yī)藥報(bào);2007年

10 ;莫?jiǎng)诶?不感冒 可防病毒性心肌炎[N];大眾衛(wèi)生報(bào);2003年

相關(guān)博士學(xué)位論文 前10條

1 張圳;miR-19b在病毒性心肌炎中作用機(jī)制的研究[D];吉林大學(xué);2017年

2 鄭楊;病毒性心肌炎心肺相關(guān)性的研究[D];黑龍江中醫(yī)藥大學(xué);2002年

3 沈茜;病毒性心肌炎病原分子雜交檢測(cè)和免疫損傷機(jī)理的實(shí)驗(yàn)研究[D];第四軍醫(yī)大學(xué);1991年

4 印芳穎;骨橋蛋白及其反義基因在病毒性心肌炎中表達(dá)及作用的研究[D];吉林大學(xué);2007年

5 王菲菲;基于病毒性心肌炎文獻(xiàn)分析的中醫(yī)證候計(jì)量診斷及用藥規(guī)律研究[D];南京中醫(yī)藥大學(xué);2009年

6 關(guān)鍵;藥物對(duì)病毒性心肌炎小鼠模型的影響[D];北京協(xié)和醫(yī)學(xué)院;2009年

7 陳相健;病毒性心肌炎向擴(kuò)張型心肌病轉(zhuǎn)化的分子細(xì)胞機(jī)制及藥物干預(yù)研究[D];南京醫(yī)科大學(xué);2001年

8 孫智勇;SB203580對(duì)病毒性心肌炎鼠的影響的實(shí)驗(yàn)研究[D];吉林大學(xué);2009年

9 張建軍;病毒性心肌炎心肌ICAM-1表達(dá)與細(xì)胞凋亡關(guān)系及藥物干預(yù)作用的實(shí)驗(yàn)研究[D];山東大學(xué);2006年

10 于俠;重組白介素-12對(duì)小鼠病毒性心肌炎治療機(jī)制的研究[D];吉林大學(xué);2007年

相關(guān)碩士學(xué)位論文 前10條

1 徐靜;K-CoxB-JN復(fù)方新制劑對(duì)小鼠CVB_3性心肌炎的治療作用[D];河北聯(lián)合大學(xué);2014年

2 董寧;ADAR1在病毒性心肌炎發(fā)病過(guò)程中作用及其機(jī)制研究[D];蘇州大學(xué);2015年

3 張鵬飛;益心解毒沖劑治療病毒性心肌炎的臨床研究[D];華北理工大學(xué);2015年

4 張蕓娟;黃芪注射液對(duì)病毒性心肌炎的治療作用及對(duì)半胱天冬氨酸蛋白酶-3活性影響的研究[D];蘭州大學(xué);2015年

5 王超;IL-33在CVB3誘導(dǎo)的病毒性心肌炎中的作用及其機(jī)制[D];蘇州大學(xué);2015年

6 周曉敏;黃芪總黃酮對(duì)病毒性心肌炎鼠心肌細(xì)胞鈣轉(zhuǎn)運(yùn)及內(nèi)質(zhì)網(wǎng)應(yīng)激作用實(shí)驗(yàn)研究[D];內(nèi)蒙古民族大學(xué);2015年

7 盧娟;腸道病毒71型病毒性心肌炎小鼠模型的建立及3-氮唑核苷的干預(yù)[D];安徽醫(yī)科大學(xué);2016年

8 徐艷艷;病毒性心肌炎小鼠體內(nèi)NT-proBNP的水平變化及意義[D];安徽醫(yī)科大學(xué);2016年

9 吳學(xué)潔;Sema7A在CVB3誘導(dǎo)的病毒性心肌炎中的作用及其機(jī)制[D];蘇州大學(xué);2016年

10 劉洪坤;基于臨床證據(jù)的中藥復(fù)方治療病毒性心肌炎組方用藥規(guī)律研究[D];山東中醫(yī)藥大學(xué);2016年

，

本文編號(hào)：2223755